Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers
暂无分享,去创建一个
J. Hainfellner | M. Preusser | R. Bartsch | C. Zielinski | G. Widhalm | P. Birner | B. Gatterbauer | A. Berghoff | S. Schur | K. Dieckmann | L. Füreder | Lisa Füreder
[1] M. Preusser,et al. 2928 Laboratory parameters have independent prognostic impact in patients with newly diagnosed brain metastases: analysis of 1201 cases , 2015 .
[2] Martin Bendszus,et al. Response assessment criteria for brain metastases: proposal from the RANO group. , 2015, The Lancet. Oncology.
[3] J. Pichler,et al. Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases , 2015, Neuropathology and applied neurobiology.
[4] A. Laxton,et al. Competing Risk Analysis of Neurologic versus Nonneurologic Death in Patients Undergoing Radiosurgical Salvage After Whole-Brain Radiation Therapy Failure: Who Actually Dies of Their Brain Metastases? , 2013, International journal of radiation oncology, biology, physics.
[5] Susan M. Chang,et al. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. , 2013, The Lancet. Oncology.
[6] J. Pichler,et al. Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases , 2012, Clinical and Experimental Metastasis.
[7] Daniela Prayer,et al. Preoperative Diffusion-Weighted Imaging of Single Brain Metastases Correlates with Patient Survival Times , 2013, PloS one.
[8] M. Preusser,et al. Optimal Management of Brain Metastases from Breast Cancer , 2013, CNS Drugs.
[9] D. Schadendorf,et al. Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. , 2012, European journal of cancer.
[10] A. Hauschild,et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.
[11] Liying Zhang,et al. Quality of life in patients with brain metastases using the EORTC QLQ-BN20+2 and QLQ-C15-PAL. , 2012, International journal of radiation oncology, biology, physics.
[12] J. Wolchok,et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.
[13] Xianghua Luo,et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Jain,et al. The biology of brain metastases—translation to new therapies , 2011, Nature Reviews Clinical Oncology.
[15] I. Fidler,et al. The seed and soil hypothesis revisited—The role of tumor‐stroma interactions in metastasis to different organs , 2011, International journal of cancer.
[16] I. Fidler. The role of the organ microenvironment in brain metastasis. , 2011, Seminars in cancer biology.
[17] M. Jenkinson,et al. Management of cerebral metastasis: evidence-based approach for surgery, stereotactic radiosurgery and radiotherapy. , 2011, European journal of cancer.
[18] P. Brown,et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. , 2009, International journal of radiation oncology, biology, physics.
[19] W. Gerald,et al. Genes that mediate breast cancer metastasis to the brain , 2009, Nature.
[20] Yoichi Watanabe,et al. A validation study of a new prognostic index for patients with brain metastases: the Graded Prognostic Assessment. , 2008, Journal of neurosurgery.
[21] Walter Curran,et al. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. , 2008, International journal of radiation oncology, biology, physics.
[22] Dennie V. Jones,et al. Response of intracranial metastases to erlotinib therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Posner,et al. Brain metastases: epidemiology and pathophysiology , 2005, Journal of Neuro-Oncology.
[24] Jill S Barnholtz-Sloan,et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Maria Werner-Wasik,et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial , 2004, The Lancet.
[26] S. Lange,et al. Adjusting for multiple testing--when and how? , 2001, Journal of clinical epidemiology.
[27] W R Markesbery,et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. , 1998, JAMA.
[28] L Gaspar,et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. , 1997, International journal of radiation oncology, biology, physics.
[29] B. Young,et al. Demographics of brain metastasis. , 1996, Neurosurgery clinics of North America.
[30] Y Maruyama,et al. A randomized trial of surgery in the treatment of single metastases to the brain. , 1990, The New England journal of medicine.
[31] J. Manson,et al. Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] D. Kondziolka,et al. The accuracy of predicting survival in individual patients with cancer. , 2014, Journal of neurosurgery.
[33] M. Campone,et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. , 2013, The Lancet. Oncology.
[34] W Curran,et al. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. , 2000, International journal of radiation oncology, biology, physics.